Role of IL-6 in shaping local immune milieus in the CNS

A07

IL-6 is increasingly identified as therapeutic target for a variety of inflammatory human diseases including Multiple Sclerosis. Due to the complexity of IL-6 directed interventions and differential responses of the distinct IL-6 signaling modalities to therapies, we now set out to investigate responses to IL-6 in the CNS in detail. We will assess the most relevant sources of IL-6 in the CNS, address the role of IL-6 signaling into conventional T cells and Foxp3+ Treg cells in the CNS during autoimmune inflammation, and finally study the impact of IL-6 on the formation of unique Treg cell niches during recovery from EAE.

Within the upcoming years we will tackle the following questions:

    1. Is continuous sensing of IL-6 required in order to maintain the encephalitogenicity (survival) of Th17 cells?
    2. Can CCR2+ myeloid cells and (to a lesser extent) B cells provide IL-6 signalling?
    3. Can molecules that are suppressed by IL-6 be used as biomarker to predict progressive disease in MS patients?

 

Heink et al., Nat Immunol., 2017

 

Principal Investigators:

Univ.-Prof. Dr. rer. nat. Ari Waisman
Institut für Molekulare Medizin
Mainz
waisman@uni-mainz.de

Univ.-Prof. Dr.med. Thomas Korn
Neurologische Universitätsklinik
TU München
thomas.korn@tum.de

News

Thu, 15/09/2022
Photo gallery: Inflammation & Imaging Symposium in the MIC building
Muenster. From September 12th to 14th scientists from Muenster University and their international guests discussed the latest developments in research on inflammation and the imaging of the immune system at the 2nd Inflammation & Imaging Symposium. The annual event is jointly organised by several research networks from Münster, among them the CRC/TRR 128 “Multiple Sclerosis”. […]...more
Tue, 28/06/2022
CRC Retreat in Münster
Muenster. After a long pause, more than 90 participants of the CRC joined in Muenster Factory Hotel to update on the latest developments. We heard the most recent on a selection of the CRC projects and there was also plenty of time for fruitful discussion and socializing in the evening....more
Mon, 23/05/2022
EU Research Council awards Lydia Sorokin Advanced Grant
Münster – The biochemist and Principal investigator of the CRC 128 Prof. Dr. Lydia Sorokin has received the coveted “Advanced Grant” awarded by the European Research Council (ERC). The funding of ca. 2.3 million euros enables the realisation of outstanding research projects. Lydia Sorokin heads the Institute for Physiological Chemistry and Pathobiochemistry at Muenster University. […]...more